advanced renal cancer
Conditions
Interventions
Case series:advanced carcinoma +CIK
Sponsors
Fujian Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Understand and sign the informed consent form and comply with the requirements of this study before proceeding with any steps related to this study; 2. Age 18-75 years old, regardless of gender; 3. The patient was pathologically diagnosed as renal cancer before admission. 4. Expected survival >=3 months; 5. ECOG3*10^9/L, Neutrophils > 1.5 *10^9/L. Hemoglobin >=85 g/L; Platelet >=50 *10^9/L; PT normal or prolonged time less than 3 seconds; Urea nitrogen and creatinine were below the upper limit of 1.5 times normal value.
Exclusion criteria
Exclusion criteria: 1. Pregnant women, lactating women or those who plan to conceive for the next one years; 2. Allergic constitution, history of allergic to blood products, known allergic to test products; 3. Systematic or long-term use of immunomodulators such as interferon, thymosin, traditional Chinese medicine, and immunosuppressive drugs such as adrenocorticosteroids within half a year; Systematic or long-term use of immunomodulators refers to the continuous standardized use of drugs for more than three months, and immunosuppressive drugs for more than one month; 4. Patients who received any cell therapy within six months (including NK, CIK, DC-CIK, stem cells, etc.); 5. Patients after organ transplantation;Patients with uncontrolled infectious diseases;Those with a history of immunodeficiency or autoimmune diseases (such as HIV,rheumatoid arthritis, Berg's disease, multiple sclerosis and type 1 diabetes mellitus, etc.); 6. those with other organ failure; 7. Those with severe mental illness; 8. Screening for evidence of drug addiction (including alcohol addiction) in the previous year; 9. Participated in clinical trials of other drugs three months before screening. 10. In the investigator's judgment, the patient has any serious acute or chronic physical or mental illness, or laboratory abnormalities that may increase the risk of study participation, or other serious conditions that may affect the interpretation of the study results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in quality of life (KPS/ECOG score);Changes in Tumor Markers (CEA199, CA125, CEA); | — |
Countries
China
Contacts
Public ContactYe Yun-bin
Fujian Cancer Hospital
Outcome results
None listed